Filing Flows › Co-Diagnostics (CODX) › Q2 2025
Co-Diagnostics (CODX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Co-Diagnostics (CODX) reported revenue of $163K for the second quarter 2025 (Q2 2025), -94% from a year earlier and +224% from the quarter before.
Co-Diagnostics, Q2 2025: revenue $163K (-94% year over year), net loss $7.7M, operating cash flow −$8.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $163K | +224% | -94% |
| Operating profit | −$8.1M | — | — |
| Net earnings | −$7.7M | — | — |
| Operating cash flow | −$8.3M | — | — |
What changed
Revenue was $163K in Q2 2025, down 94% year over year and up 224% from the previous quarter.
Gross margin was 80.3%, down 11.7 points from a year earlier. Operating costs exceeded revenue by $8.1M, an operating margin of -4946.1%. Operating expenses fell 19% while revenue fell 94%. The quarter ended with a net loss of $7.7M, wider than the previous quarter's $7.5M loss.
Operating cash flow was −$8.3M. Non-cash charges added back $291K of depreciation and amortization and $580K of share-based compensation. Working capital and other items used $1.4M. Capital expenditures of $401K exceeded it, leaving free cash flow of −$8.7M.
Questions
What was Co-Diagnostics' revenue in the second quarter 2025?
Co-Diagnostics (CODX) reported revenue of $163K for the second quarter 2025 (Q2 2025), -94% from a year earlier and +224% from the quarter before.
Source: Co-Diagnostics 10-Q on SEC EDGAR.